Share on StockTwits

Sangamo Biosciences (NASDAQ:SGMO) SVP Philip D. Gregory sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $15.66, for a total transaction of $234,900.00. Following the completion of the sale, the senior vice president now directly owns 109,347 shares in the company, valued at approximately $1,712,374. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Sangamo Biosciences (NASDAQ:SGMO) traded down 1.59% on Thursday, hitting $16.14. The stock had a trading volume of 186,501 shares. Sangamo Biosciences has a 52-week low of $7.97 and a 52-week high of $24.69. The stock’s 50-day moving average is $14.68 and its 200-day moving average is $16.51. The company’s market cap is $1.097 billion.

Sangamo Biosciences (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.12) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.01. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. During the same quarter last year, the company posted ($0.13) earnings per share. Sangamo Biosciences’s revenue was up 76.1% compared to the same quarter last year. Analysts expect that Sangamo Biosciences will post $-0.29 EPS for the current fiscal year.

Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.